>
>
Immune Checkpoint Inhibitors Market - By Type (PD-1, PD-L1, CTLA-4), Application (Lung Cancer, Breast Cancer, Bladder Cancer, Melanoma, Cervical Cancer), End-use (Hospitals & Clinics, Cancer Centers), Global Forecast 2024 – 2032
Download Free PDF

Immune Checkpoint Inhibitors Market
Get a free sample of this reportGet a free sample of this report Immune Checkpoint Inhibitors Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 12
Tables & Figures: 212
Countries covered: 22
Pages: 120
Download Free PDF
Immune Checkpoint Inhibitors Market Size
Immune Checkpoint Inhibitors Market size was valued at USD 47.4 billion and is projected to grow at a CAGR of 16.7% from 2024 to 2032. This market is witnessing strong growth, primarily driven by the increasing global cancer prevalence and a rising demand for advanced, personalized cancer therapies.
Immune checkpoint inhibitors enhance the immune system's ability to identify and attack cancer cells. They have shown significant effectiveness against various cancers, such as melanoma, lung cancer, and renal cell carcinoma. The growing adoption of these therapies is supported by extensive clinical trials, favorable regulatory approvals, and their integration into established treatment protocols, all of which drive market growth.
Moreover, increased investments in oncology research, along with a strong pipeline of new immune checkpoint inhibitors, are expected to sustain this market's growth. For example, in July 2021, the Rankin government pledged an investment of USD 18 million to improve cancer therapies, including immune checkpoint inhibitors. In 2023, the Cancer Research Institute allocated USD 28 million in grants specifically for cancer immunotherapy research. Such support from governmental and organizational entities is crucial in driving the immune checkpoint inhibitors market.
Immune checkpoint inhibitors are a specialized class of drugs in cancer therapy. They work by blocking proteins known as checkpoints, which are part of the immune system. These checkpoints help regulate the immune response, ensuring it does not harm normal cells. By blocking these checkpoints, immune checkpoint inhibitors enhance the ability of immune cells, especially T cells, to recognize and attack cancer cells.
Immune Checkpoint Inhibitors Market Trends
Immune Checkpoint Inhibitors Market Analysis
Based on the type, the market is categorized into PD-1, PD-L1, CTLA-4, and other types. The PD-1 segment dominated the market with USD 34.7 billion in 2023.
The immune checkpoint inhibitors market is segmented by application into lung cancer, breast cancer, bladder cancer, melanoma, cervical cancer, Hodgkin lymphoma, colorectal cancer, and other applications. In 2023, the lung cancer segment led the market, commanding a 25.1% share.
Segmented by end-use, the immune checkpoint inhibitors market includes hospitals & clinics, cancer centers, and academic & research institutes. In 2023, hospitals & clinics led the market and are projected to grow at a CAGR of 16.5% from 2024 to 2032.
In 2023, the North American immune checkpoint inhibitors market was valued at USD 22.9 billion, with projections indicating robust growth at a CAGR of 16.8% from 2024 to 2032.
In 2023, the U.S. immune checkpoint inhibitors market was valued at USD 20.7 billion.
The Asia Pacific region is set to experience a notable growth spurt, projected at a CAGR of 17% during the forecast period.
India's immune checkpoint inhibitors market is poised for significant growth.
Immune Checkpoint Inhibitors Market Share
The competitive landscape of the market is characterized by intense rivalry among leading pharmaceutical companies and biotech firms. Major players such as Bristol-Myers Squibb, Merck & Co., and Roche dominate the market with their flagship products like Opdivo, Keytruda, and Tecentriq, respectively. These companies are heavily investing in ongoing clinical trials and research to expand the indications for their existing therapies and develop novel checkpoint inhibitors.
Additionally, emerging biotech firms are entering the market with innovative approaches and novel targets, contributing to a dynamic and rapidly evolving competitive environment. Strategic collaborations, mergers and acquisitions, and significant investments in research and development are key strategies employed by these companies to maintain their competitive edge and drive growth in the market.
Immune Checkpoint Inhibitors Market Companies
Few of the prominent players operating in immune checkpoint inhibitors industry include:
Immune Checkpoint Inhibitors Market News:
The immune checkpoint inhibitors market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:
Click here to Buy Section of this Report
Market, By Type
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries: